The Research Question How often do patients with musculoskeletal (MSK) complaints newly treated with NSAIDs, subsequently consult their GP because of an.

Slides:



Advertisements
Similar presentations
Practical Management of MS in the Primary Care Office Setting Case Study 3.
Advertisements

Choice, Risk and Safety in the PCT context Peter Mansell NPSA and Maria Dineen Consequence UK.
Implementing NICE guidance
Walsall Healthcare NHS Trust Medicines Management.
© Safeguarding public health Innovation; issues for regulators, society and industry. Overview of Conference topics Alasdair Breckenridge Medicines and.
{ ADVERSE DRUG REACTIONS To ensure patient, family/caregiver and home health personnel are instructed to identify adverse reactions to medications and.
Primary care of hypertensive patients and the risk of acute events Irina Stirbu-Wagner Markus MJ Nielen Maaike Langelaan Robert A. Verheij Joke C. Korevaar.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December 2007.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2009.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2014.
MEDICINES and Older People Hira Singh Prescribing Adviser (Middlesbrough PCT and Redcar & Cleveland PCT Medicines Management Team) March 2008.
The Pharmaceutical Care of Patients with Long Term Conditions Deirdre Watt Team Leader, Community Pharmacy Scottish Government.
Measuring the Severity of Medication Discrepancies: A Community Pharmacy Perspective.
Pharmacists’ Expanded Scope of Practice in Canada as of Oct 2014 Source: Canadian Pharmacists Association.
Collecting data in clinic.  Aim of BADBIR  Definition of Adverse Events  Adverse events in BADBIR  Adverse event recording in hospital case notes.
Primary Care Trigger Tool Manaia Health PHO Linda Holman Quality Leader.
Topic 6 Understanding and managing clinical risk.
Standard 4: Medication Safety Advice Centre Network Meeting Margaret Duguid Pharmaceutical Advisor February 2013.
ANDREA LD ANti-psychotic Drug REduction in primary care for Adults with Learning Disabilities (ANDREA-LD): A Randomised Double-blind Placebo Controlled.
DIVISION OF REPRODUCTIVE AND UROLOGIC PRODUCTS Physician Labeling Rule Lisa Soule, M.D.
Study designs. Kate O’Donnell General Practice & Primary Care.
Signal identification and development I.Ralph Edwards.
Minimum requirements for Pharmacovigilance in countries.
Impact of Multidisciplinary Team Care on Older People with Polypharmacy Liang-Kung Chen Center for Geriatrics and Gerontology Taipei Veterans General Hospital.
European Patients’ Academy on Therapeutic Innovation Introduction to pharmacovigilance Monitoring the safety of medicines.
Suicide Data Information for London CCG Mental Health Leads Henrietta Hughes March 2015.
Medicines adherence Implementing NICE guidance 2009 NICE clinical guideline 76.
Denis G. Patterson, DO ECHO Project April 20, 2016 CDC Guidelines for Prescribing Opioids for Chronic Pain.
PMP Outcomes. Background to Chronic Pain One of the most prevalent physical complaints - defined as prolonged pain of at least 3 months’ duration 10-20%
1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.
Grant Macdonald.  Appropriate polypharmacy describes treatment where a patient has multiple morbidities, and/or a complex condition, that is being managed.
R. Papani, A. G. Duarte, Y-L. Lin, G. Sharma
Choosing Wisely Pharmacy’s Role and Recommendations Mary Wong
Prescribing for the Oldest Old
Fracture Liaison Service Database
Detection & monitoring of ADR
Cover slide.
Understanding and learning from errors and managing clinical risks
EudraVigilance.
Alcohol, Other Drugs, and Health: Current Evidence
Improving Adverse Drug Reaction Information in Product Labels
Brahmajee K. Nallamothu, MD, MPH
Martha Carvour, MD, PhD March 2, 2017
3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.
Medication Adherence Improve the health of your patients and reduce overall health care costs.
Medicines Management Tips & Preparing for your CQC Inspection with Gerry Devine Practice Management Advisor.
9. Introduction to signal detection
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Treating Alcohol Abuse
Department of Health Management and Informatics
Information for Network Providers
Prior authorization and patient cost-sharing are least likely to be seen as effective in reducing unnecessary care. “How effective do you think each of.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Medication Adherence Improve the health of your patients and reduce overall health care costs.
Dr Nick Harper Deputy Medical Director
Tolerability of Isoniazid Preventive therapy Among HIV infected Cohort in Nigeria Folajinmi Oluwasina Strategic Information Unit AIDS Healthcare Foundation,
Improving your Safety Culture?
The Research Question How and why do primary care physicians (PCPs) use medications including antipsychotics, as well as non-pharmacologic strategies,
The Research Question Aim TIA is defined by short-lasting symptoms
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Non-Pharmacological Therapies, Chronic Pain and Opioid Addictions
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Essentials of Good Pain Care: A Team-Based Approach
Clair Huckerby Consultant Pharmacist
High-risk use of over-the-counter non-steroidal anti-inflammatory drugs: a population-based cross-sectional study by Aafke R Koffeman, Vera E Valkhoff,
Alcohol, Other Drugs, and Health: Current Evidence
Massachusetts Consultation Service for the Treatment of Addiction and Pain (MCSTAP) Offers real-time phone consultation to primary care practices on safe.
Is Primary Care Safe? HAPIA Conference 2014 Peter Walsh
Presentation transcript:

The Research Question How often do patients with musculoskeletal (MSK) complaints newly treated with NSAIDs, subsequently consult their GP because of an adverse drug reaction (ADR)? AR Koffeman, AR van Buul, VE Valkhoff, GW ‘t Jong, PJE Bindels, J van der Lei, MCJM Sturkenboom, PAJ Luijsterburg, SMA Bierma-Zeinstra Why is this important? GPs frequently treat MSK complaints with NSAIDs The occurrence of serious NSAID-related ADRs has been studied extensively Less known about the incidence of non-serious ADRs in primary care and resulting health care utilization in the form of GP consultations

What the Researchers Did Population/Subjects 16, 626 adult patients newly treated with an NSAID by their GP because of a MSK complaint Design Cohort study performed within a large electronic healthcare database Basic Method/Intervention Manual assessment of the electronic medical record of included patients for the duration of NSAID use (with a maximum of 2 months), to determine whether the GP was reconsulted because of an adverse event Causality assessment to estimate the likelihood that the adverse events was causally related to the use of the NSAID

What the Researchers Found 995 (6%) consulted their GP because of at least one adverse event In total 1271 adverse events were presented by these 995 patients The most frequent adverse events presented were dyspepsia (31.3%), dyspnea (12%) and skin reactions (11%) After causality assessment, 215 adverse events were classified a likely ADR, 515 as a possible ADR This means that 4% of patients prescribed an NSAID for the treatment of a MSK complaint, subsequently consulted their GP because of a likely or possible ADR

What This Means for Clinical Practice In primary care patients with MSK complains treated with NSAIDs, one in 25 were found to reconsult their GP because of a possible or likely ADR The true incidence of ADRs is likely to be higher, as not all patients suffering from an ADR will consult their GP; some may choose to discontinue NSAID treatment without further consultation GPs should address not only the risk of serious ADRs when discussing treatment options for MSK complaints with their patients, but also our finding of reconsultation for non-serious ADRs Although these non-serious ADRs are less harmful to the patient, they lead to an increase in primary health care utilization and may outweigh the benefits of NSAID treatment for many patients